Table 2.
Molecular characteristics of the 239 classified tumors
| Overall population (n = 239) | Progressive disease group (n = 75) | Controlled disease group (n = 164) | P | |
|---|---|---|---|---|
| EGFR gene (%)1 | ||||
| Wild-type | 82 (34.3) | 29 (36.7) | 53 (32.3) | 0.002 |
| Mutated | 19 (7.9) | 0 (0) | 19 (11.6) | |
| Unknown3 | 138 (57.8) | 46 (61.3) | 92 (56.1) | |
| KRAS gene (%)1 | ||||
| Wild-type | 102 (42.7) | 33 (44.0) | 69 (42.1) | 0.531 |
| Mutated | 9 (3.8) | 2 (2.7) | 7 (4.3) | |
| Unknown3 | 128 (53.6) | 40 (53.3) | 88 (53.6) | |
| EML4-ALK translocation (%)2 | ||||
| Presence | 4 (1.7) | 0 (0) | 4 (2.4) | 0.293 |
| Absence | 38 (15.9) | 13 (17.3) | 25 (15.2) | |
| Unknown3 | 197 (82.4) | 62 (82.7) | 135 (82.3) | |
1
Chi-squared test.
2
Fisher's exact test.
3
Missing data have been suppressed for the statistical analyses.